Alisol B 23-Acetate Ameliorates Lipopolysaccharide-Induced Intestinal Barrier Dysfunction by Inhibiting TLR4-NOX1/ROS Signaling Pathway in Caco-2 Cells

Abstract

Alisol B 23-Acetate (AB23A) is a naturally occurring triterpenoid, which can be indicated in the rhizome of medicinal and dietary plants from Alisma species. Previous studies have demonstrated that AB23A could inhibit intestinal permeability by regulating tight junction (TJ)-related proteins. Even so, the AB23A protective mechanism against intestinal barrier dysfunction remains poorly understood. This investigation seeks to evaluate the AB23A protective effects on intestinal barrier dysfunction and determine the mechanisms for restoring intestinal barrier dysfunction in LPS-stimulated Caco-2 monolayers. According to our findings, AB23A attenuated the inflammation by reducing pro-inflammatory cytokines production like IL-6, TNF-α, IL-1β, and prevented the paracellular permeability by inhibiting the disruption of TJ in LPS-induced Caco-2 monolayers after treated with LPS. AB23A also inhibited LPS-induced TLR4, NOX1 overexpression and subsequent ROS generation in Caco-2 monolayers. Transfected with NOX1-specific shRNA diminished the up-regulating AB23A effect on ZO-1 and occludin expression. Moreover, transfected with shRNA of TLR4 not only enhanced ZO-1 and occludin expression but attenuated NOX1 expression and ROS generation. Therefore, AB23A ameliorates LPS-induced intestinal barrier dysfunction by inhibiting TLR4-NOX1/ROS signaling pathway in Caco-2 monolayers, suggesting that AB23A may have positive impact on maintaining the intestinal barrier’s integrity.

Protective effects and potential mechanisms of fermented egg-milk peptides on the damaged intestinal barrier

“…VEGF signaling pathway and EGFR tyrosine kinase inhibitor resistance were listed here with an enrichment score of 59.06 and 51.46, respectively. Meanwhile, many pathways related to intestinal health, such as the TLR signaling pathway ( 27 ), MAPK signaling pathway ( 28 ), and Rap1 signaling pathway, were enriched with a high enrichment score.…”

Dexmedetomidine alleviates intestinal barrier dysfunction and inflammatory response in mice via suppressing TLR4/MyD88/NF-κB signaling in an experimental model of ulcerative colitis

“…Pathological changes related to UC include ulcer formation, intestinal epithelial barrier disruption, and gut inflammation [35]. The intestinal epithelial barrier is made up of epithelial cell monolayer with intercellular tight junctions composed of claudin-1, occludin, and ZO-1 that modulate intestinal permeability [36][37][38][39] . Excessive apoptosis of intestinal epithelial cells leads to intestinal barrier dysfunction and has been considered as a main pathogenic mechanism of chronic intestinal inflammation [40] Previously, 1 ml of 5% acetic acid was administered to male C57BL/6 mice to induce UC; then, serum levels of inflammatory cytokines (IL-6 and TNF-α) were increased and colonic cell apoptosis was induced [41].…”

Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations

“…Generally, as the culture time and cell density increase, the cells exhibit more structural and functional characteristics resembling those of the small intestine. According to Xia et al [93], once the cells demonstrate differentiation and form complete monolayers on Transwell filter supports, the transmembrane resistance can be monitored using a cellular transmembrane resistivity meter (TEER > 300). This measurement helps determine whether the Caco-2 monoculture model meets the necessary criteria for in vitro intestinal barrier modeling.…”